INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
2.530
+0.170 (7.20%)
At close: Jul 3, 2025, 1:00 PM
2.550
+0.020 (0.79%)
After-hours: Jul 3, 2025, 4:53 PM EDT
INmune Bio Stock Forecast
Stock Price Forecast
The 4 analysts that cover INmune Bio stock have a consensus rating of "Buy" and an average price target of $9.53, which forecasts a 276.68% increase in the stock price over the next year. The lowest target is $0.6 and the highest is $20.
Price Target: $9.53 (+276.68%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for INmune Bio stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Strong Buy Maintains $30 → $8 | Strong Buy | Maintains | $30 → $8 | +216.21% | Jul 2, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 1, 2025 |
| Scotiabank | Scotiabank | Buy → Sell Downgrades $23 → $0.6 | Buy → Sell | Downgrades | $23 → $0.6 | -76.28% | Jul 1, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $22 → $30 | Strong Buy | Maintains | $22 → $30 | +1,085.77% | Feb 13, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $22 → $23 | Buy | Maintains | $22 → $23 | +809.09% | Feb 11, 2025 |
Financial Forecast
Revenue This Year
25.50K
from 14.00K
Increased by 82.14%
Revenue Next Year
7.36M
from 25.50K
Increased by 28,750.98%
EPS This Year
-1.75
from -2.11
EPS Next Year
-1.82
from -1.75
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 52,500 | 15.2M | 25.5M | ||
| Avg | 25,500 | 7.4M | 22.6M | ||
| Low | n/a | 2.2M | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 275.0% | 59,351.0% | 246.6% | ||
| Avg | 82.1% | 28,751.0% | 207.0% | ||
| Low | - | 8,354.9% | 166.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.61 | -1.17 | -0.83 | ||
| Avg | -1.75 | -1.82 | -1.32 | ||
| Low | -1.94 | -2.16 | -1.62 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.